Long-term follow up of patients with human immunodeficiency virus infection and advanced stage Hodgkin's lymphoma treated with doxorubicin, bleomycin, vinblastine and dacarbazine

被引：7
|
作者：
Xicoy, Blanca [1 ]
Miralles, Pilar [2 ]
Morgades, Mireia [1 ]
Rubio, Rafael [3 ]
Valencia, Maria-Eulalia [4 ]
Ribera, Josep-Maria [1 ]
机构：
[1] Univ Autonoma Barcelona, ICO Hosp Germans Trias Pujol, Jose Carreras Leukemia Res Inst, Dept Clin Hematol, Badalona, Spain
[2] Hosp Gregorio Maranon, Dept Infect Dis, Madrid, Spain
[3] Hosp 12 Octubre, Dept Infect Dis, E-28041 Madrid, Spain
[4] Hosp Carlos III, Dept Infect Dis, Madrid, Spain
来源：
HAEMATOLOGICA | 2013年 / 98卷 / 08期
关键词：
Hodgkin's lymphoma; HIV-related; long-term follow up; opportunistic infections; second cancers; ACTIVE ANTIRETROVIRAL THERAPY; IMPACT; REGIMEN; HAART;
D O I：
10.3324/haematol.2012.079921
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：E85 / E86
页数：2
相关论文
共 45 条
  • [1] Limited prognostic value of the International Prognostic Score in advanced stage human immunodeficiency virus infection-related Hodgkin lymphoma treated with the doxorubicin, bleomycin, vinblastine, and dacarbazine regimen
    Xicoy, Blanca
    Ribera, Josep-Maria
    Miralles, Pilar
    Berenguer, Juan
    Rubio, Rafael
    Mahillo, Beatriz
    Valencia, Maria-Eulalia
    Abella, Eugenia
    Lopez-Guillermo, Armando
    Sureda, Ana
    Morgades, Mireia
    Navarro, Jose-Tomas
    Esteban, Herminia
    LEUKEMIA & LYMPHOMA, 2009, 50 (10) : 1718 - 1720
  • [2] Results of treatment with doxorubicin, bleomycin, vinblastine and dacarbazine and highly active antiretroviral therapy in advanced stage, human immunodeficiency virus-related Hodgkin's lymphoma
    Xicoy, Blanca
    Ribera, Josep-Maria
    Miralles, Pilar
    Berenguer, Juan
    Rubio, Rafael
    Mahillo, Beatriz
    Valencia, Maria-Eulalia
    Abella, Eugenia
    Lopez-Guillermo, Armando
    Sureda, Ana
    Morgades, Mireia
    Navarro, Jose-Tomas
    Esteban, Herminia
    Mate, J. L.
    Cosin, J.
    Lopez, J. C.
    Pulido, F.
    Moreno, V
    Cepeda, C.
    Gonzalez, J.
    Tellez, M. J.
    Vergas, J.
    Estrada, V
    Roca, V
    Montes, M. L.
    Arribas, J. R.
    Gonzalez-Garcia, J.
    Lacruz, J.
    Lopez, J.
    Salavert, M.
    Santos, J.
    Palacios, R.
    Marquez, M.
    Sepulveda, M. A.
    de la Torre, A.
    Rivero, A.
    Garcia, M.
    Pintado, V
    Antela, A.
    Patier, L.
    Rodriguez, L., I
    HAEMATOLOGICA, 2007, 92 (02) : 191 - 198
  • [3] Neutropenia and febrile neutropenia in patients with Hodgkin's lymphoma treated with doxorubicin (Adriamycin), bleomycin, vinblastine and dacarbazine (ABVD) chemotherapy
    Chand, VK
    Link, BK
    Ritchie, JM
    Shannon, M
    Wooldridge, JE
    LEUKEMIA & LYMPHOMA, 2006, 47 (04) : 657 - 663
  • [4] Prognostic Factors for Advanced-Stage Human Immunodeficiency Virus-Associated Classical Hodgkin Lymphoma Treated With Doxorubicin, Bleomycin, Vinblastine, and Dacarbazine Plus Combined Antiretroviral Therapy A Multi-Institutional Retrospective Study
    Castillo, Jorge J.
    Bower, Mark
    Bruehlmann, Jeremy
    Novak, Urban
    Furrer, Hansjakob
    Tanaka, Paula Y.
    Besson, Caroline
    Montoto, Silvia
    Cwynarski, Kate
    Abramson, Jeremy S.
    Dalia, Samir
    Bibas, Michele
    Connors, Joseph M.
    Furman, Michael
    Minh-Ly Nguyen
    Cooley, Timothy P.
    Beltran, Brady E.
    Collins, Jaime A.
    Vose, Julie M.
    Xicoy, Blanca
    Ribera, Josep-Maria
    CANCER, 2015, 121 (03) : 423 - 431
  • [5] Benefits of BV-AVD (Brentuximab vedotin, doxorubicin, vinblastine, and dacarbazine) versus ABVD (doxorubicin hydrochloride, bleomycin sulfate, vinblastine sulfate, dacarbazine) in patients with advanced-stage Hodgkin's lymphoma: an analysis of the ECHELON 1 trial by the GATLA group using the Delphi Method
    Pavlovsky, Astrid
    Altuve, Juan Ignacio Garcia
    Cerutti, Amalia
    Fiad, Lorena
    Kurgansky, Nicolas
    Warley, Fernando
    Aranguren, Florencia Negri
    HEMATOLOGY TRANSFUSION AND CELL THERAPY, 2024, 46 : S250 - S256
  • [6] HIV Status Does Not Influence Outcome in Patients With Classical Hodgkin Lymphoma Treated With Chemotherapy Using Doxorubicin, Bleomycin, Vinblastine, and Dacarbazine in the Highly Active Antiretroviral Therapy Era
    Montoto, Silvia
    Shaw, Kate
    Okosun, Jessica
    Gandhi, Shreyans
    Fields, Paul
    Wilson, Andrew
    Shanyinde, Milensu
    Cwynarski, Kate
    Marcus, Robert
    de Vos, Johannes
    Young, Anna Marie
    Tenant-Flowers, Melinda
    Orkin, Chloe
    Johnson, Margaret
    Chilton, Daniella
    Gribben, John G.
    Bower, Mark
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (33) : 4111 - 4116
  • [7] Prognostic Implication of the Absolute Lymphocyte to Absolute Monocyte Count Ratio in Patients With Classical Hodgkin Lymphoma Treated With Doxorubicin, Bleomycin, Vinblastine, and Dacarbazine or Equivalent Regimens
    Vassilakopoulos, Theodoros P.
    Dimopoulou, Maria N.
    Angelopoulou, Maria K.
    Petevi, Kyriaki
    Pangalis, Gerassimos A.
    Moschogiannis, Maria
    Dimou, Maria
    Boutsikas, George
    Kanellopoulos, Alexandros
    Gainaru, Gabriella
    Plata, Eleni
    Flevari, Pagona
    Koutsi, Katerina
    Papageorgiou, Loula
    Telonis, Vassilios
    Tsaftaridis, Panayiotis
    Sachanas, Sotirios
    Yiakoumis, Xanthoula
    Tsirkinidis, Pantelis
    Viniou, Nora-Athina
    Siakantaris, Marina P.
    Variami, Eleni
    Kyrtsonis, Marie-Christine
    Meletis, John
    Panayiotidis, Panayiotis
    Konstantopoulos, Kostas
    ONCOLOGIST, 2016, 21 (03) : 343 - 353
  • [8] A successful initiation of treatment of Hodgkin's lymphoma with adriamycin-bleomycin-vinblastine-dacarbazine dose reduction in a patient with fulminant hepatic failure and co-infection with human immunodeficiency virus and hepatitis B
    Veeraballi, Sindhusha
    Chan, Kok H.
    Slim, Jihad
    Shaaban, Hamid S.
    Guron, Gunwant
    JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 2022, 28 (02) : 479 - 485
  • [9] Prognostic value of lesion dissemination in doxorubicin, bleomycin, vinblastine, and dacarbazine-treated, interimPET-negative classical Hodgkin Lymphoma patients: A radio-genomic study
    Durmo, Rexhep
    Donati, Benedetta
    Rebaud, Louis
    Cottereau, Anne Segolene
    Ruffini, Alessia
    Nizzoli, Maria Elena
    Ciavarella, Sabino
    Vegliante, Maria Carmela
    Nioche, Christophe
    Meignan, Michel
    Merli, Francesco
    Versari, Annibale
    Ciarrocchi, Alessia
    Buvat, Irene
    Luminari, Stefano
    HEMATOLOGICAL ONCOLOGY, 2022, 40 (04) : 645 - 657
  • [10] What is the Price of survival in Hodgkin's lymphoma?: Long-term follow-up of cured patients
    Zsofia, Miltenyi
    Katalin, Keresztes
    Judit, Vegh
    Gyorgy, Szekely
    Arpad, Illes
    HEMATOLOGICAL ONCOLOGY, 2007, 25 (04) : 178 - 183
12345